Inhibition of YAP for breaking tumor immune tolerance
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 8, 2022
Grant Date -
Jan 25, 2018
app pub date -
Feb 12, 2016
filing date -
Feb 12, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Yes-associated protein (Yap), a downstream co-activator of the Hippo pathway, is highly expressed in the Treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in Drosophila melanogaster, the Hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals. Loss of Yap expression in Treg cells can lead to superior anti-tumor immune responses, and thus, Yap is an important immunotherapeutic target for cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully